Research

Adherence

High out-of-pocket costs for semaglutide create a socioeconomic barrier to access, resulting in significantly lower prescription rates among low-income individuals despite them having a higher prevalence of obesity.

If you are on a limited budget, the high out-of-pocket cost of semaglutide may prevent you from accessing it, even if you have obesity. This is a systemic issue where low-income individuals are undertreated. Advocacy for reimbursement or subsidies is needed to address this inequality.

GoodSupportsHIGH confidence
This suggests that economic concerns lead to a systematic undertreatment for obesity for low-income individuals, potentially exacerbating existing health inequalities.
Rasmus Bo Hasselbalch et al. · The Lancet Regional Health - Europe · 2025

Why this rating

Large population-based register study (N=4.5M) with robust statistical adjustment.

Source

Association between socioeconomic factors and semaglutide use for weight loss: a population-based cross-sectional study in Denmark

Rasmus Bo Hasselbalch et al. · The Lancet Regional Health - Europe · 2025

cross_sectional · n=4531146Cited 7×
Read the paper

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →